NCT01923857View on ClinicalTrials.gov

Evaluation of Pharmacokinetic and Safety Profile of Androxal in Male Subjects With Impaired Renal Function

PHASE1CompletedINTERVENTIONAL
Enrollment

26

Participants

Timeline

Start Date

August 31, 2013

Primary Completion Date

August 31, 2014

Study Completion Date

August 31, 2014

Conditions
Secondary Hypogonadism
Interventions
DRUG

Androxal 25 mg

Trial Locations (2)

33014

Miami

55404

Minneapolis

All Listed Sponsors
lead

Repros Therapeutics Inc.

INDUSTRY

NCT01923857 - Evaluation of Pharmacokinetic and Safety Profile of Androxal in Male Subjects With Impaired Renal Function | Biotech Hunter | Biotech Hunter